Short answer
Solid Biosciences Inc. (SLDB) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$54M
- −17.9% YoY · +1.6% QoQ
- EPS (diluted)
- −$0.35
- +27.1% YoY · +2.8% QoQ
Source: XBRL data from the Solid Biosciences Inc. (SLDB) Q3 2026 10-Q on SEC EDGAR. USD.
Solid Biosciences Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, no commercial product revenue, unchanged from prior-year quarter
- Net loss $53.9M vs $45.8M YoY, operating expenses $57.7M vs $48.1M
- Best-performing program SGT-212, R&D expense $4.4M, up 144.3% YoY
- Cash, equivalents and securities $348.9M, sufficient into first half of 2028
- Operating cash use $145.4M, financing provided $303.4M, including $226.3M private placement proceeds
Risk Factors
- Newly added regulatory risk: evolving FDA trial-design expectations may require randomized trials, larger populations or longer follow-up
- Most material regulatory update: FDA workforce reductions and proposed HHS budget cuts could delay IND and BLA reviews
- Operational risk: transient-transfection manufacturing remains complex, with capacity constraints potentially delaying clinical supply
- Competitive risk: Sarepta’s ELEVIDYS approval and competitors’ Duchenne programs intensify pressure on SGT-003
- Financial risk: cash, cash equivalents and securities expected to fund operations only into the first half of 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Solid Biosciences Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.